Summary
Schizophrenia is associated with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling. The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely associated signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathology of schizophrenia. Efficacy of mGlu5 positive allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function. To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq–mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus. Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models. These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not critical for in vivo efficacy.
3-Amino-1,2,4-benzotriazine 1,4-dioxide (SR4233, WIN59075,
tirapazamine, 1) is a clinically promising
antitumor agent that requires bioreductive activation, selectively
kills oxygen-deficient cells, and is believed to derive
its biological activity from DNA cleavage. Using a
xanthine−xanthine oxidase enzyme system as a
one-electron
reductant to activate 1 for DNA cleavage, it has been found
that radical scavengers such as mannitol, dimethyl
sulfoxide, ethanol, methanol, and tert-butyl alcohol
significantly inhibit drug-dependent DNA cleavage.
Compound
1, in concert with the xanthine−xanthine oxidase system,
converts DMSO to methanesulfinic acid, a reaction
characteristic of hydroxyl radical. In addition, treatment of a
32P-labeled restriction fragment with
reductively-activated 1 results in cleavage at every base pair, with
little sequence specificity, consistent with involvement of
a
highly reactive, nonselective agent such as hydroxyl radical.
These results strongly support the involvement of
radicals in the cleavage of DNA by 1 and are consistent with
hydroxyl radical as the major DNA-cleaving species
generated by reduction of 1.
Background
Metabotropic glutamate receptor subtype 5 (mGlu5) activators have emerged as a novel approach to the treatment of schizophrenia. Positive allosteric modulators (PAMs) of mGlu5 have generated tremendous excitement and fueled major drug discovery efforts. Although mGlu5 PAMs have robust efficacy in preclinical models of schizophrenia, preliminary reports suggest that these compounds may induce seizure activity. Prototypical mGlu5 PAMs do not activate mGlu5 directly but selectively potentiate activation of mGlu5 by glutamate. This mechanism may be critical to maintaining normal activity-dependence of mGlu5 activation and achieving optimal in vivo effects.
Methods
Using specially engineered mGlu5 cell lines incorporating point mutations within the allosteric and orthosteric binding sites, as well as brain slice electrophysiology and in vivo electroencephalography and behavioral pharmacology, we found that some mGlu5 PAMs have intrinsic allosteric agonist activity in the absence of glutamate.
Results
Both in vitro mutagenesis and in vivo pharmacology studies demonstrate that VU0422465 is an agonist PAM that induces epileptiform activity and behavioral convulsions in rodents. In contrast, VU0361747, an mGlu5 PAMs optimized to eliminate allosteric agonist activity, has robust in vivo efficacy and does not induce adverse effects at doses that yield high brain concentrations.
Conclusions
Loss of the absolute dependence of mGlu5 PAMs on glutamate release for their activity can lead to severe adverse effects. The finding that closely related mGlu5 PAMs can differ in their intrinsic agonist activity provides critical new insights that is essential for advancing these molecules through clinical development for treatment of schizophrenia.
Positive allosteric modulators (PAMs)
of the M4 muscarinic
acetylcholine receptor (mAChR) represent a novel approach for the
treatment of psychotic symptoms associated with schizophrenia and
other neuropsychiatric disorders. We recently reported that the selective
M4 PAM VU0152100 produced an antipsychotic drug-like profile
in rodents after amphetamine challenge. Previous studies suggest that
enhanced cholinergic activity may also improve cognitive function
and reverse deficits observed with reduced signaling through the N-methyl-d-aspartate subtype of the glutamate receptor
(NMDAR) in the central nervous system. Prior to this study, the M1 mAChR subtype was viewed as the primary candidate for these
actions relative to the other mAChR subtypes. Here we describe the
discovery of a novel M4 PAM, VU0467154, with enhanced in vitro potency and improved pharmacokinetic properties
relative to other M4 PAMs, enabling a more extensive characterization
of M4 actions in rodent models. We used VU0467154 to test
the hypothesis that selective potentiation of M4 receptor
signaling could ameliorate the behavioral, cognitive, and neurochemical
impairments induced by the noncompetitive NMDAR antagonist MK-801.
VU0467154 produced a robust dose-dependent reversal of MK-801-induced
hyperlocomotion and deficits in preclinical models of associative
learning and memory functions, including the touchscreen pairwise
visual discrimination task in wild-type mice, but failed to reverse
these stimulant-induced deficits in M4 KO mice. VU0467154
also enhanced the acquisition of both contextual and cue-mediated
fear conditioning when administered alone in wild-type mice. These
novel findings suggest that M4 PAMs may provide a strategy
for addressing the more complex affective and cognitive disruptions
associated with schizophrenia and other neuropsychiatric disorders.
Herein we report the discovery and SAR of a novel series of SARS-CoV 3CLpro inhibitors identified through the NIH Molecular Libraries Probe Production Centers Network (MLPCN). In addition to ML188, ML300 represents the second probe declared for 3CLpro from this collaborative effort. The X-ray structure of SARS-CoV 3CLpro bound with a ML300 analog highlights a unique induced-fit reorganization of the S2-S4 binding pockets leading to the first sub-micromolar non-covalent 3CLpro inhibitors retaining a single amide bond.
The G-protein activated, inward-rectifying potassium (K + ) channels, "GIRKs", are a family of ion channels (K ir 3.1-K ir 3.4) that has been the focus of intense research interest for nearly two decades. GIRKs are comprised of various homo-and heterotetrameric combinations of four different subunits. These subunits are expressed in different combinations in a variety of regions throughout the central nervous system and in the periphery. The body of GIRK research implicates GIRK in processes as diverse as controlling heart rhythm, to effects on reward/addiction, to modulation of response to analgesics. Despite years of GIRK research, very few tools exist to selectively modulate GIRK channels' activity and until now no tools existed that potently and selectively activated GIRKs. Here we report the development and characterization of the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810). We further demonstrate that ML297 is active in two in vivo models of epilepsy, a disease where up to 40% of patients remain with symptoms refractory to present treatments. The development of ML297 represents a truly significant advancement in our ability to selectively probe GIRK's role in physiology as well as providing the first tool for beginning to understand GIRK's potential as a target for a diversity of therapeutic indications.
Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu 5 ) have emerged as an exciting new approach for the treatment of schizophrenia and other central nervous system (CNS) disorders. Of interest, some mGlu 5 PAMs act as pure PAMs, only potentiating mGlu 5 responses to glutamate whereas others [allosteric agonists coupled with PAM activity (ago-PAMs)] potentiate responses to glutamate and have intrinsic allosteric agonist activity in mGlu 5 -expressing cell lines. All mGlu 5 PAMs previously shown to have efficacy in animal models act as ago-PAMs in cell lines, raising the possibility that allosteric agonist activity is critical for in vivo efficacy. We have now optimized novel mGlu 5 pure PAMs that are devoid of detectable agonist activity and structurally related mGlu 5 ago-PAMs that activate mGlu 5 alone in cell lines. Studies of mGlu 5 PAMs in cell lines revealed that ago-PAM activity is dependent on levels of mGlu 5 receptor expression in human embryonic kidney 293 cells, whereas PAM potency is relatively unaffected by levels of receptor expression. Furthermore, ago-PAMs have no agonist activity in the native systems tested, including cortical astrocytes and subthalamic nucleus neurons and in measures of long-term depression at the hippocampal Schaffer collateral-CA1 synapse. Finally, studies with pure PAMs and ago-PAMs chemically optimized to provide comparable CNS exposure revealed that both classes of mGlu 5 PAMs have similar efficacy in a rodent model predictive of antipsychotic activity. These data suggest that the level of receptor expression influences the ability of mGlu 5 PAMs to act as allosteric agonists in vitro and that ago-PAM activity observed in cell-based assays may not be important for in vivo efficacy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.